NCT06910813 - DFT383 in Pediatric Participants With Nephropathic Cystinosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

August 26, 2030

Study Completion Date

August 26, 2030

Conditions

Nephropathic Cystinosis

Interventions

GENETIC

DFT383

DFT383 is an autologous hematopoietic stem cell (HSC) gene therapy.

Trial Locations (4)

RECRUITING

Emory University School of Medicine / Children's Healthcare of Atlanta (recuiting Cohort 0), Atlanta

RECRUITING

Baylor College of Medicine - Texas Children's Hospital (recuiting Cohort 0), Houston

RECRUITING

University of California at San Diego / Rady Children's Hospital, San Diego

RECRUITING

Stanford University / Stanford Children's Health, Stanford